



Contact: Jack DeFranco
Location: San Diego, CA, USA
Email: jack.defranco@targeson.com
Tel: 858.605.1623
Website: www.targeson.com



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health



National Institutes of Health Commercialization Assistance Program
 (NIH-CAP)

Company Profile

Industry Sector: Health care:

Subsector: In vivo diagnostics

Overview: Targeson, Inc. develops, manufactures and markets ultrasound-based molecular imaging agents for the medical research market. Targeson has a sustainable business in the academic research market that will generate revenue and enable the company to leverage the technology for a clinical product development program. Targeson has already launched several products for use in the research market, including first-in-class angiogenesis targeted imaging agents.

Target Markets: Academic research, pharmaceutical research, and pre-clinical contract research organizations

Key Value Drivers

Technology: Acoustically active microspheres coated with specific targeting ligands that adhere to molecular markers of disease, then imaged by ultrasound to identify diseases (tumor angiogenesis, atherosclerosis, inflammation and cardiac ischemia) at the molecular level. The microspheres are engineered to be translatable to human use.

Competitive Advantage:

		Targeson
Direct competition:	Limited products (2)	6
	Requires activation	Ready to use
	Limited stability (1 hour)	1 working day
	No targeted agents	Unique agents

Other imaging modalities compared to ultrasound: Radioactive, more expensive, not real time, not all molecular, not all translatable to humans, not portable, requires chemistry, takes hours

Plan & Strategy: Build sales in the research markets, engineering microspheres that will be translatable for human use, and licensed to pharma or diagnostic companies.

Management

Jack DeFranco, President & CEO

More than 30 years of healthcare industry experience and entrepreneurial success with 3 start-ups

Klaus Ley, MD, Chief Medical Officer

Director of the Division of Inflammation Biology at the La Jolla Institute for Allergy and Immunology in La Jolla, CA., a biomedical engineer with 20 years of experience studying the biomechanics and molecular properties of adhesion molecules, and is an international expert on inflammatory diseases.

Joshua Rychak, PhD, Vice President, Research

Co-founder and industry expert and researcher in the field of ultrasound molecular imaging with extensive experience in testing targeted contrast agent adhesion *in vitro* and in animal models of tumor angiogenesis and inflammation.

Product Pipeline

Current Research Market Products				
Targestar P				
Targestar P-HF				
Targestar SA				
Visistar Integrin				
Visistar VEGFR2				
Visistar VCAM1				
Research Market Pipeline		2012	2013	2014
Visistar P Selectin				
Targosphere delivery agent				
Visistar MADCAM				
Visistar E Selectin				
Clinical License Opportunities				
Prostate Cancer				